Literature DB >> 19358018

Tumor vaccines for breast cancer.

Karen S Anderson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19358018      PMCID： PMC3432638          DOI： 10.1080/07357900802574421

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


× No keyword cloud information.
  110 in total

Review 1.  The B7 family revisited.

Authors:  Rebecca J Greenwald; Gordon J Freeman; Arlene H Sharpe
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

Review 2.  HLA antigen changes in malignant tumors of mammary epithelial origin: molecular mechanisms and clinical implications.

Authors:  Michael Campoli; Chien-Chung Chang; Sharon A Oldford; Allison D Edgecombe; Sheila Drover; Soldano Ferrone
Journal:  Breast Dis       Date:  2004

3.  Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.

Authors:  Kristin Sanderson; Ronald Scotland; Peter Lee; Dongxin Liu; Susan Groshen; Jolie Snively; Shirley Sian; Geoffrey Nichol; Thomas Davis; Tibor Keler; Michael Yellin; Jeffrey Weber
Journal:  J Clin Oncol       Date:  2004-12-21       Impact factor: 44.544

Review 4.  Immunosuppressive networks in the tumour environment and their therapeutic relevance.

Authors:  Weiping Zou
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

5.  Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.

Authors:  Michael A Morse; Timothy M Clay; Amy C Hobeika; Takuya Osada; Shubi Khan; Stephen Chui; Donna Niedzwiecki; Dennis Panicali; Jeffrey Schlom; H Kim Lyerly
Journal:  Clin Cancer Res       Date:  2005-04-15       Impact factor: 12.531

Review 6.  Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9.

Authors:  Jörg Vollmer
Journal:  Expert Opin Biol Ther       Date:  2005-05       Impact factor: 4.388

7.  Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.

Authors:  M E Christine Lutsiak; Roshanak T Semnani; Roberto De Pascalis; Syed V S Kashmiri; Jeffrey Schlom; Helen Sabzevari
Journal:  Blood       Date:  2004-12-09       Impact factor: 22.113

8.  Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

Authors:  Daniel E Speiser; Danielle Liénard; Nathalie Rufer; Verena Rubio-Godoy; Donata Rimoldi; Ferdy Lejeune; Arthur M Krieg; Jean-Charles Cerottini; Pedro Romero
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

9.  Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer.

Authors:  Zhen Su; Jens Dannull; Benjamin K Yang; Philipp Dahm; Doris Coleman; Donna Yancey; Sylvia Sichi; Donna Niedzwiecki; David Boczkowski; Eli Gilboa; Johannes Vieweg
Journal:  J Immunol       Date:  2005-03-15       Impact factor: 5.422

10.  B7-h4 is highly expressed in ductal and lobular breast cancer.

Authors:  Barbara Tringler; Shaoqiu Zhuo; Glenn Pilkington; Kathleen C Torkko; Meenakshi Singh; M Scott Lucia; David E Heinz; Jackie Papkoff; Kenneth R Shroyer
Journal:  Clin Cancer Res       Date:  2005-03-01       Impact factor: 12.531
View more
  16 in total

Review 1.  Cancer immunotherapy: a promising dawn in cancer research.

Authors:  Banashree Bondhopadhyay; Sandeep Sisodiya; Atul Chikara; Asiya Khan; Pranay Tanwar; Dil Afroze; Neha Singh; Usha Agrawal; Ravi Mehrotra; Showket Hussain
Journal:  Am J Blood Res       Date:  2020-12-15

2.  Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: A model-based characterization approach.

Authors:  Belén P Solans; Ascensión López-Díaz de Cerio; Arlette Elizalde; Luis Javier Pina; Susana Inogés; Jaime Espinós; Esteban Salgado; Luis Daniel Mejías; Iñaki F Trocóniz; Marta Santisteban
Journal:  Br J Clin Pharmacol       Date:  2019-06-14       Impact factor: 4.335

3.  Immune effect and safety evaluation of vaccine prepared by dendritic cells modified by rAAV-carrying BCSG1 gene.

Authors:  W-H Wang; C-H Zhou; J Ding; Y-X Zhang; L-L Zheng; S-F Chen; W Zhang
Journal:  Gene Ther       Date:  2016-08-24       Impact factor: 5.250

4.  Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer.

Authors:  Kenji Gonda; Masahiko Shibata; Tohru Ohtake; Yoshiko Matsumoto; Kazunoshin Tachibana; Noriko Abe; Hitoshi Ohto; Kenichi Sakurai; Seiichi Takenoshita
Journal:  Oncol Lett       Date:  2017-06-02       Impact factor: 2.967

5.  Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma.

Authors:  Mikayel Mkrtichyan; Anahit Ghochikyan; Hayk Davtyan; Nina Movsesyan; Dmitry Loukinov; Victor Lobanenkov; David H Cribbs; Amanda K Laust; Edward L Nelson; Michael G Agadjanyan
Journal:  Cell Immunol       Date:  2011-05-12       Impact factor: 4.868

Review 6.  Immunotherapy for the treatment of breast cancer.

Authors:  Brenda Ernst; Karen S Anderson
Journal:  Curr Oncol Rep       Date:  2015-02       Impact factor: 5.075

Review 7.  Current status of mucins in the diagnosis and therapy of cancer.

Authors:  Satyanarayana Rachagani; Maria P Torres; Nicolas Moniaux; Surinder K Batra
Journal:  Biofactors       Date:  2009 Nov-Dec       Impact factor: 6.113

Review 8.  Progress in the development of a therapeutic vaccine for breast cancer.

Authors:  Andrew L Coveler; Nicole E Bates; Mary L Disis
Journal:  Breast Cancer (Dove Med Press)       Date:  2010-06-04

9.  Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy.

Authors:  Jacques Thibodeau; Marie-Claude Bourgeois-Daigneault; Réjean Lapointe
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

10.  Alpha-Type 1 Polarized Dendritic Cells Loaded with Apoptotic Allogeneic Breast Cancer Cells Can Induce Potent Cytotoxic T Lymphocytes against Breast Cancer.

Authors:  Min-Ho Park; Deok-Hwan Yang; Mi-Hyun Kim; Jae-Hong Jang; Yoon-Young Jang; Youn-Kyung Lee; Chun-Ji Jin; Than Nhan Nguyen Pham; Truc Anh Nguyen Thi; Mi-Seon Lim; Hyun-Ju Lee; Cheol Yi Hong; Jung-Han Yoon; Je-Jung Lee
Journal:  Cancer Res Treat       Date:  2011-03-31       Impact factor: 4.679
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.